Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2019

01-09-2019 | Acute Promyelocytic Leukemia | Review Article

A candidate for lung cancer treatment: arsenic trioxide

Authors: W. Huang, Y. C. Zeng

Published in: Clinical and Translational Oncology | Issue 9/2019

Login to get access

Abstract

Arsenic trioxide (ATO), a highly effective drug in treating acute promyelocytic leukemia with low toxicity, demonstrates a significant effect on lung cancer. The anti-cancer mechanisms of ATO include inhibition of cancer stem-like cells, induction of apoptosis, anti-angiogenesis, sensitization of chemotherapy and radiotherapy, anti-cancer effects of hypoxia, and immunoregulation properties. In addition, some studies have reported that different lung cancers respond differently to ATO. It was concluded on numerous studies that the rational combination of administration and encapsulation of ATO have promising potentials in increasing drug efficacy and decreasing adverse drug effects. We reviewed the efficacy of ATO in the treatment of lung cancer in recent years to provide some views for further study.
Literature
1.
2.
Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;6(Suppl 2):3–10.CrossRefPubMed
3.
Lengfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012;26(3):433–42.CrossRefPubMed
4.
Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001;6(Suppl 2):1–2.CrossRefPubMed
5.
Zhang X, Jia S, Yang S, Yang Y, Yang T, Yang Y. Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J Cell Biochem. 2012;113(11):3528–35.CrossRefPubMed
6.
Gao JK, Wang LX, Long B, Ye XT, Su JN, Yin XY, et al. Arsenic trioxide inhibits cell growth and invasion via down- regulation of Skp2 in pancreatic cancer cells. Asian Pac J Cancer Prev. 2015;16(9):3805–10.CrossRefPubMed
7.
Walker AM, Stevens JJ, Ndebele K, Tchounwou PB. Evaluation of arsenic trioxide potential for lung cancer treatment: assessment of apoptotic mechanisms and oxidative damage. J Cancer Sci Ther. 2016;8(1):1–9.CrossRefPubMed
8.
Liu Y, Hock JM, Van Beneden RJ, Li X. Aberrant overexpression of FOXM1 transcription factor plays a critical role in lung carcinogenesis induced by low doses of arsenic. Mol Carcinog. 2014;53(5):380–91.CrossRefPubMed
9.
Perona R, Lopez-Ayllon BD, de Castro Carpeno J, Belda-Iniesta C. A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin Transl Oncol. 2011;13(5):289–93.CrossRefPubMed
10.
Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res. 2013;19(8):1972–80.CrossRefPubMedPubMedCentral
11.
He B, Barg RN, You L, Xu Z, Reguart N, Mikami I, et al. Wnt signaling in stem cells and non-small-cell lung cancer. Clin Lung Cancer. 2005;7(1):54–60.CrossRefPubMed
12.
Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS ONE. 2012;7(6):e38996.CrossRefPubMedPubMedCentral
13.
Hong Z, Bi A, Chen D, Gao L, Yin Z, Luo L. Activation of hedgehog signaling pathway in human non-small cell lung cancers. Pathol Oncol Res. 2014;20(4):917–22.CrossRefPubMed
14.
Chang KJ, Yang MH, Zheng JC, Li B, Nie W. Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer. Am J Transl Res. 2016;8(2):1133–43.PubMedPubMedCentral
15.
Zhen Y, Zhao S, Li Q, Li Y, Kawamoto K. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett. 2010;292(1):64–72.CrossRefPubMed
16.
Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology. 2002;181–182:475–81.CrossRefPubMed
17.
Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 2013;138(2):255–71.CrossRefPubMed
18.
Leung LL, Lam SK, Li YY, Ho JC. Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma. Oncol Lett. 2017;14(3):3748–54.CrossRefPubMedPubMedCentral
19.
Chen H, Gu S, Dai H, Li X, Zhang Z. Dihydroartemisinin sensitizes human lung adenocarcinoma A549 cells to arsenic trioxide via apoptosis. Biol Trace Elem Res. 2017;179(2):203–12.CrossRefPubMed
20.
Walker AM, Stevens JJ, Ndebele K, Tchounwou PB. Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells. Int J Environ Res Public Health. 2010;7(5):1996–2007.CrossRefPubMedPubMedCentral
21.
Qu GP, Xiu QY, Li B, Liu YA, Zhang LZ. Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia. Toxicol Ind Health. 2009;25(8):505–15.CrossRefPubMed
22.
Han YH, Kim SZ, Kim SH, Park WH. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 2008;270(1):40–55.CrossRefPubMed
23.
Wei L, Wang XW, Zuo WS. Toxicity of arsenic trioxide to human lung adenocarcinoma cell line SPCA1 and its mechanism. Ai Zheng. 2004;23(12):1633–8.PubMed
24.
Dong J, Wu Y, Dong X, Xu L, Liu L. Cell cycle arrest and apoptosis induced by arsenic trioxide in human lung cancer cell line. Zhongguo Fei Ai Za Zhi. 2000;3(6):435–7.PubMed
25.
26.
27.
Shi Y, Liu Y, Huo J, Gao G. Arsenic trioxide induced apoptosis and expression of p53 and bcl-2 genes in human small cell lung cancer cells. Zhonghua Jie He He Hu Xi Za Zhi. 2002;25(11):665–6.PubMed
28.
Lam SK, Li YY, Zheng CY, Leung LL, Ho JC. E2F1 downregulation by arsenic trioxide in lung adenocarcinoma. Int J Oncol. 2014;45(5):2033–43.CrossRefPubMed
29.
Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 2006;79(4):173–89.CrossRefPubMedPubMedCentral
30.
Duclos C, Lavoie C, Denault JB. Caspases rule the intracellular trafficking cartel. FEBS J. 2017;284(10):1394–420.CrossRefPubMed
31.
O’Brien DI, Nally K, Kelly RG, O’Connor TM, Shanahan F, O’Connell J. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets. 2005;9(5):1031–44.CrossRefPubMed
32.
Li X, You M, Liu YJ, Ma L, Jin PP, Zhou R, et al. Reversal of the apoptotic resistance of non-small-cell lung carcinoma towards TRAIL by natural product toosendanin. Sci Rep. 2017;7:42748.CrossRefPubMedPubMedCentral
33.
Bhojani MS, Rossu BD, Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biol Ther. 2003;2(4 Suppl 1):S71–8.PubMed
34.
Wang JY, Zhao XQ, Wang CM, Mo BW, Jiang M, Chen F. Arsenic trioxide enhances TRAIL inducing human lung cancer cell line A549 cells apoptosis by down-regulate the expression of NF-kappaB. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012;43(6):834–8.PubMed
35.
Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–32.CrossRefPubMed
36.
Jiang X, Chen C, Liu Y, Zhang P, Zhang Z. Critical role of cellular glutathione homeostasis for trivalent inorganic arsenite-induced oxidative damage in human bronchial epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014;770:35–45.CrossRefPubMed
37.
Zheng CY, Lam SK, Li YY, Ho JC. Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity. Int J Oncol. 2015;46(3):1067–78.PubMed
38.
Gu S, Chen C, Jiang X, Zhang Z. ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells. Chem Biol Interact. 2016;245:100–9.CrossRefPubMed
39.
Gu S, Chen C, Jiang X, Zhang Z. Study on the resveratrol and arsenic trioxide combination induced apoptosis and its mechanism on lung adenocarcinoma cells. Wei Sheng Yan Jiu. 2016;45(1):87–92.PubMed
40.
Gu S, Chen C, Jiang X, Zhang Z. Resveratrol synergistically triggers apoptotic cell death with arsenic trioxide via oxidative stress in human lung adenocarcinoma A549 cells. Biol Trace Elem Res. 2015;163(1–2):112–23.CrossRefPubMed
41.
Han YH, Kim SH, Kim SZ, Park WH. Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels. J Cell Biochem. 2008;104(3):862–78.CrossRefPubMed
42.
Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.CrossRefPubMed
43.
Li H, Zhu X, Zhang Y, Xiang J, Chen H. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction. J Exp Clin Cancer Res. 2009;28:110.CrossRefPubMedPubMedCentral
44.
Han B, Zhou G, Zhang Q, Zhang J, Wang X, et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol. 2004;4(4):335–42.PubMed
45.
Gu S, Lai Y, Chen H, Liu Y, Zhang Z. miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells. Sci Rep. 2017;7(1):12155.CrossRefPubMedPubMedCentral
46.
Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, et al. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014;348(3):360–71.CrossRefPubMed
47.
Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, Kang CM, et al. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res. 2004;64(24):8960–7.CrossRefPubMed
48.
49.
Khan Z, Khan AA, Yadav H, Prasad G, Bisen PS. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell Mol Biol Lett. 2017;22:8.CrossRefPubMedPubMedCentral
50.
Cheng Y, Chang LW, Tsou TC. Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol. 2006;80(6):310–8.CrossRefPubMed
51.
Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7):1323–34.CrossRefPubMed
52.
Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res. 2007;13(23):6938–46.CrossRefPubMed
53.
Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL, Ho JC. Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma. Int J Oncol. 2014;44(6):2093–102.CrossRefPubMed
54.
Bunn PA Jr. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002;29(3 Suppl 9):17–22.CrossRefPubMed
55.
Kailashiya C, Sharma HB, Kailashiya J. Telomerase based anticancer immunotherapy and vaccines approaches. Vaccine. 2017;35(43):5768–75.CrossRefPubMed
56.
Cheng Y, Li Y, Ma C, Song Y, Xu H, Yu H, et al. Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction. Oncotarget. 2016;7(11):12682–92.CrossRefPubMedPubMedCentral
57.
Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, et al. Angiogenesis inhibitors in NSCLC. Int J Mol Sci. 2017;18(10):2021.CrossRefPubMedCentral
58.
59.
Yang MH, Zang YS, Huang H, Chen K, Li B, Sun GY, et al. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr Cancer Drug Targets. 2014;14(6):557–66.CrossRefPubMed
60.
Xie SL, Yang MH, Chen K, Huang H, Zhao XW, Zang YS, et al. Efficacy of arsenic trioxide in the treatment of malignant pleural effusion caused by pleural metastasis of lung cancer. Cell Biochem Biophys. 2015;71(3):1325–33.CrossRefPubMed
61.
Yang MH, Chang KJ, Zheng JC, Huang H, Sun GY, Zhao XW, et al. Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation. Oncol Lett. 2017;14(3):3103–9.CrossRefPubMedPubMedCentral
62.
Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer. 2015;121(8):E1–6.CrossRefPubMed
63.
Li C, Sun BQ, Gai XD. Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours. Clin Transl Oncol. 2014;16(7):593–8.CrossRefPubMed
64.
Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC. Combination of arsenic trioxide and chemotherapy in small cell lung cancer. Lung Cancer. 2013;82(2):222–30.CrossRefPubMed
65.
Li HC, Wang CX, Huang C, Wang LF, Mu XY, Jiang SJ, et al. Effect and mechanism of arsenic trioxide on chemosensitivity of human lung adenocarcinoma cells. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26(11):689–92.PubMed
66.
Chen F, Sui G, Chen H, Cui Y. The influence of arsenic trioxide combined with cisplatin on the growth and expression of X-linked inhibitor of apoptosis protein, XIAP of human non-small cell lung cancer cells. Zhongguo Fei Ai Za Zhi. 2007;10(3):168–71.PubMed
67.
Suzuki T, Ishibashi K, Yumoto A, Nishio K, Ogasawara Y. Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells. Oncol Lett. 2015;10(2):805–9.CrossRefPubMedPubMedCentral
68.
Wang C, Pan Z, Hou H, Li D, Mo Y, Mo C, et al. The enhancement of radiation sensitivity in nasopharyngeal carcinoma cells via activation of the Rac1/NADPH signaling pathway. Radiat Res. 2016;185(6):638–46.CrossRefPubMed
69.
Morgan MA, Lawrence TS. Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways. Clin Cancer Res. 2015;21(13):2898–904.CrossRefPubMedPubMedCentral
70.
Diepart C, Karroum O, Magat J, Feron O, Verrax J, Calderon PB, et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res. 2012;72(2):482–90.CrossRefPubMed
71.
Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, et al. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene. 2005;24(3):390–8.CrossRefPubMed
72.
Shen J, Qu GP, Xiu QY, Li B. Effects of arsenic trioxide on apoptosis and proliferation of human lung cancer cells under hypoxia. Zhong Xi Yi Jie He Xue Bao. 2008;6(3):274–7.CrossRefPubMed
73.
Wang H, Gao P, Zheng J. Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells. Biochem Biophys Res Commun. 2014;451(4):556–61.CrossRefPubMed
74.
Lee MH, Cho Y, Kim DH, Woo HJ, Yang JY, Kwon HJ, et al. Menadione induces G2/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1. Am J Transl Res. 2016;8(12):5246–55.PubMedPubMedCentral
75.
Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cell. Mol Cancer Ther. 2009;8(1):160–70.CrossRefPubMed
76.
Gao Q, Jiang J, Chu Z, Lin H, Zhou X, Liang X. Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity. Oncol Lett. 2017;13(4):2141–50.CrossRefPubMedPubMedCentral
77.
Wang L, Wang R, Fan L, Liang W, Liang K, Xu Y, et al. Arsenic trioxide is an immune adjuvant in liver cancer treatment. Mol Immunol. 2017;81:118–26.CrossRefPubMed
78.
Thomas-Schoemann A, Batteux F, Mongaret C, Nicco C, Chereau C, Annereau M, et al. Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. J Immunol. 2012;189(11):5171–7.CrossRefPubMed
79.
Yang X, Lin D. Changes of 2015 WHO histological classification of lung cancer and the clinical significance. Zhongguo Fei Ai Za Zhi. 2016;19(6):332–6.PubMed
80.
Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther. 2009;8(1):160–70.CrossRefPubMed
81.
Lam SK, Leung LL, Li YY, Zheng CY, Ho JC. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma. Lung Cancer. 2016;101:111–9.CrossRefPubMed
82.
Wu DD, Lau ATY, Yu FY, Cai NL, Dai LJ, Ok Kim M, et al. Extracellular signal-regulated kinase 8-mediated NF-kappaB activation increases sensitivity of human lung cancer cells to arsenic trioxide. Oncotarget. 2017;8(30):49144–55.PubMedPubMedCentral
83.
Leslie EM. Arsenic-glutathione conjugate transport by the human multidrug resistance proteins (MRPs/ABCCs). J Inorg Biochem. 2012;108:141–9.CrossRefPubMed
84.
Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmuller S, Karnthaler-Benbakka C, et al. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther. 2013;12(6):1073–84.CrossRefPubMed
85.
86.
Jiang TT, Brown SL, Kim JH. Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro. J Exp Clin Cancer Res. 2004;23(2):259–62.PubMed
87.
Park JH, Kim EJ, Jang HY, Shim H, Lee KK, Jo HJ, et al. Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008;20(2):379–84.PubMed
88.
Jin HO, Yoon SI, Seo SK, Lee HC, Woo SH, Yoo DH, et al. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol. 2006;72(10):1228–36.CrossRefPubMed
89.
Jin HO, Seo SK, Woo SH, Lee HC, Kim ES, Yoo DH, et al. A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung Cancer. 2008;61(3):317–27.CrossRefPubMed
90.
Mandegary A, Torshabi M, Seyedabadi M, Amirheidari B, Sharif E, Ghahremani MH. Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways. Biomed Res Int. 2013;2013:237543.CrossRefPubMedPubMedCentral
91.
Seo SK, Kim JH, Choi HN, Choe TB, Hong SI, Yi JY, et al. Knockdown of TWIST1 enhances arsenic trioxide- and ionizing radiation-induced cell death in lung cancer cells by promoting mitochondrial dysfunction. Biochem Biophys Res Commun. 2014;449(4):490–5.CrossRefPubMed
92.
Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, et al. A first-in-class TWIST1 inhibitor with activity in oncogene-driven lung cancer. Mol Cancer Res. 2017;15(12):1764–76.CrossRefPubMedPubMedCentral
93.
Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Vannini I, et al. Combining anti-mir-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res. 2017;23(11):2891–904.CrossRefPubMed
94.
Gu SY, Chen HY, Dai HM, Li XY, Zhang ZZ. miR-155/BACH1 signaling pathway in human lung adenocarcinoma cell death induced by arsenic trioxide. Sichuan Da Xue Xue Bao Yi Xue Ban. 2017;48(6):828–33.PubMed
95.
Jiang X, Chen C, Gu S, Zhang Z. Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide. Environ Toxicol Pharmacol. 2017;57:141–50.CrossRefPubMed
96.
Akhtar A, Xiaoyan Wang S, Ghali L, Bell C, Wen X. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. J Biomed Res. 2017;31(3):177–88.PubMedPubMedCentral
97.
Chen H, Ahn R, Van den Bossche J, Thompson DH, O’Halloran TV. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther. 2009;8(7):1955–63.CrossRefPubMedPubMedCentral
98.
Xiao X, Liu Y, Guo M, Fei W, Zheng H, Zhang R, et al. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo. J Biomater Appl. 2016;31(1):23–35.CrossRefPubMed
Metadata
Title
A candidate for lung cancer treatment: arsenic trioxide
Authors
W. Huang
Y. C. Zeng
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02054-6

Other articles of this Issue 9/2019

Clinical and Translational Oncology 9/2019 Go to the issue

Research Article

Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study

Research Article

Differential expression of S1P receptor subtypes in human bladder transitional cell carcinoma

Research Article

Incidence and survival of central nervous system tumors in childhood and adolescence in Girona (Spain) 1990–2013: national and international comparisons

Research Article

Laparoscopic cytoreductive surgery and HIPEC is effective regarding peritoneum tissue paclitaxel distribution

Research Article

Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment

Brief Research Article

Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits